Colin Bristow
Stock Analyst at UBS
(1.76)
# 3,298
Out of 5,173 analysts
105
Total ratings
40.32%
Success rate
-1.79%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $7.31 | +36.80% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $451.24 | +21.00% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $137.34 | -18.45% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $66.42 | +20.45% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $4.34 | +15.21% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $2.20 | -54.55% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $24.38 | -30.27% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $349.77 | -8.80% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.71 | +47.60% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.77 | +4.59% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $115.68 | +3.73% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $183.64 | +10.00% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.47 | +988.44% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $736.53 | +49.21% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $17.71 | +842.97% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $910.55 | -53.87% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $10.66 | -81.24% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.94 | +827.84% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $204.93 | -28.76% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $57.00 | +31.58% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.56 | +915.63% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.99 | +80.36% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $7.31
Upside: +36.80%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $451.24
Upside: +21.00%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $137.34
Upside: -18.45%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $66.42
Upside: +20.45%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $4.34
Upside: +15.21%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $2.20
Upside: -54.55%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $24.38
Upside: -30.27%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $349.77
Upside: -8.80%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.71
Upside: +47.60%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.77
Upside: +4.59%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $115.68
Upside: +3.73%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $183.64
Upside: +10.00%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.47
Upside: +988.44%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $736.53
Upside: +49.21%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $17.71
Upside: +842.97%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $910.55
Upside: -53.87%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $10.66
Upside: -81.24%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.94
Upside: +827.84%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $204.93
Upside: -28.76%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $57.00
Upside: +31.58%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.56
Upside: +915.63%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $4.99
Upside: +80.36%